Gapping up
In reaction to earnings/guidance:
- CWH +7.6%, NLSN +6.1% (also divests its Global Connect Business to Advent International for $2.7 bln), EL +5.6%, LITE +5.5%, BCC +4.9%, HSIC +4%, AMCX +3.5%, EGRX +2.9%, CLX +2.3%, IAA +2%, CDW +1.5%, LDOS +1.2%, FE +1%, WM +1%, MPLX +0.9%, LL +0.6%
Select index ETFs showing strength:
- DIA +1.5%, SPY +1.2%, IWM +1.2%, QQQ +0.8%
Other news:
- DBVT +72.7% (announces filing and validation of Marketing Authorization Application for Viaskin Peanut by EMA)
- DNOW +13.5% (announces that Dick Alario has stepped down from his short-term role as Exec Vice Chairman)
- NIO +10.6% (reports October deliveries increased 100.1% yr/yr)
- LI +7.5% (reports deliveries of 3,692 Li ONEs in October, representing a steady increase compared to September)
- XPEV +7% (reports October deliveries increased 229% yr/yr to 3040 vehicles)
- RYTM +6.3% (reports results from Phase 3 clinical trials of Setmelanotide published in The Lancet Diabetes & Endocrinology)
- DNKN +6.2% (to be acquired by Inspire Brands for $106.50 per shar)
- GCO +3.5% (announced that Melvin Tucker, senior vice president and CFO has resigned his position, effective November 27, 2020, in order to pursue an opportunity outside of the Company, and will assist in ensuring a smooth transition)
- GRWG +2.7% (to acquire The GrowBiz)
- NRZ +2.4% (authorized the repurchase of up to $100 million of the Company's preferred stock)
- SNY +2.1% (to acquire Kiadis Pharma for EUR308 mln)
- CSTL +1.7% (announces commercial launch of DecisionDx DiffDx-Melanoma)
- EVA +1.5% (increases quarterly distribution to $0.775/unit from $0.765/unit) GM +1.4% (appoints Paul Jacobson as CFO, effective December 1)
- NVS +1.4% (reports positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig)
- BDX +1.2% (receives order for more than nine million 15-minute COVID-19 Antigen Tests from Dutch Ministry of Health)
- IMUX +1.1% (announces 200 patients enrolled in its phase 2 CALVID-1 Trial of IMU-838 for the treatment of moderate covid-19, allowing for main phase 2 efficacy analysis to proceed)
- TLSA +1% (initiates clinical trial with Covid-19 patients in Brazil with nasally administered Foralumab)
Analyst comments:
- HEAR +4.6% (upgraded to Outperform from Neutral at Wedbush)
- PLT +3.7% (upgraded to Overweight from Neutral at JP Morgan)
- UAA +3.3% (upgraded to Buy from Hold at Stifel)
- WYNN +3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- JRVR +2.7% (upgraded to Buy from Neutral at Compass Point)
- COP +1.4% (upgraded to Buy from Neutral at BofA Securities)